Glaucoma drug Roclatan shows superior efficacy in late-stage study


Aerie Pharmaceuticals has reported successful efficacy results for the phase III Mercury 2 trial on Roclatan, a fixed dose combination of Rhopressa (netarsudil ophthalmic solution, 0.02%) and latanoprost for treatment of elevated IOP.[Read More …] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/glaucoma-drug-roclatan-shows-superior-efficacy-in-late-stage-study/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s